Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 1058 (1 October 2008) | doi:10.1038/nbt1008-1058a
Heplisav's topline
Abstract
The investigational hepatitis B vaccine Heplisav could provide difficult-to-immunize patients with more robust protection than that offered by currently marketed vaccines. Heplisav—jointly developed by Berkeley, California–based Dynavax and partner Merck of Whitehouse Station, New Jersey—was evaluated against London-based GlaxoSmithKline's Engerix-B in a phase 3 trial in patients with end-stage renal disease.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
